Days 4 and 5 at ASCO17 showed off the overall scope of immunotherapy’s efforts to provide clinical benefits to patients. Many next-generation immune-based treatments were discussed, including some of which may represent the future standard of care for some cancers. Below are some of the most important findings revealed during the final two days of the conference:
Multiple Tumor Types:
Watch our story about Carol, one of the patients treated on this trial.
Head and Neck Cancer:
ASCO17: Day 3 Immunotherapy Highlights
Read Previous Article
ASCO17 Recap: 7 Takeaways from the World’s Premier Clinical Cancer Conference
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Behind-the-scenes of a new based-on-a-true-story comedy web series, “Homesick,” about an American living in London with a woman battling cancer and her nine-year-old daughter.
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only chemotherapy and radiation